NCT01557764撤回2 期
A Phase II Study of Lapatinib in Combination With Trastuzumab in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Overall clinical benefit rate (CBR; CD + PR + SD) of lapatinib and trastuzumab in patients with breast cancer that carry HER2 mutations
研究概览
简要总结
This phase II trial studies the effectiveness of lapatinib ditosylate (lapatinib) together with trastuzumab in treating patients with HER2-negative breast cancer that carries HER2 gene mutations. Lapatinib may kill tumor cells by blocking some of the enzymes needed for cell division and growth. Trastuzumab, a monoclonal antibody, may block the ability of tumor cells to grow and spread. Giving lapatinib together with trastuzumab may provide a more effective treatment for patients with this type of cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have histologically or cytologically confirmed metastatic breast cancer
- •The breast cancer has been tested negative for HER2 (0 or 1+ by immunohistochemistry [IHC] or non-amplified by fluorescence in-situ hybridization [FISH])
- •Patient may have measurable or evaluable disease
- •If given prior radiotherapy and/or prior chemotherapy, the patient must have completed radiation therapy and be at least 1 week from the last chemotherapy administration, with adequate recovery of bone marrow and organ functions, before starting lapatinib or trastuzumab
- •* Note that the HER2 sequencing analysis can be performed while patient is receiving other systemic therapies so the results could be used to determine whether the patient is eligible to receive lapatinib and trastuzumab when disease progresses from current therapy
- •Patient must have had at least one lines of systemic therapy for metastatic breast cancer
- •Patient must have disease that progressed on his/her most recent treatment regimen
- •Patient must be > 18 years of age.
- •Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- •Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) unless due to Gilbert's syndrome
- •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 3.0 x IULN with/without liver metastases
- •Creatinine =< 1.5 x IULN
- •Patient must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) to be eligible for study treatment; to avoid the cost of screening, patients with known recent LVEF < LLN or symptoms of congestive heart failure are not eligible for registration
- •Women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
- •Patient (or legally authorized representative if applicable) must be able to understand and willing to sign an institutional review board (IRB) approved written informed consent document
- •Patients with known treated brain metastasis are eligible, but must have received radiation and be off steroids and stable for 3 months
- •Patients meeting all inclusion criteria listed above and exclusion criteria will be registered to undergo HER2 mutation analysis; only patients with mutations in HER2 either in the primary or metastatic tumor are eligible for study therapy with lapatinib and trastuzumab; those without mutations in HER2 are not eligible for study drug therapy; information and tissue collected from patients without HER2 mutations will be used for molecular epidemiology studies of HER2 negative breast cancer
排除标准
- •Patient must not be receiving any other investigational agents
- •Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Patient must not have acute or currently active/requiring antiviral therapy hepatic or biliary disease (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment)
- •Patient must not be pregnant and/or breastfeeding
- •Patient must not have a history of significant cardiac disease, cardiac risk factors, or uncontrolled arrhythmias
- •Patient must not have symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest
研究组 & 干预措施
Treatment (enzyme inhibitor and monoclonal antibody)
Experimental
Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: lapatinib ditosylate (Drug)
Treatment (enzyme inhibitor and monoclonal antibody)
Experimental
Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: trastuzumab (Biological)
结局指标
主要结局
Overall clinical benefit rate (CBR; CD + PR + SD) of lapatinib and trastuzumab in patients with breast cancer that carry HER2 mutations
时间窗: 6 months
Responses assessed using RECIST guidelines version 1.1; duration of SD must be \>= 6 months; CBR and its 80% confidence interval will be calculated.
次要结局
- PFS of patients treated with lapatinib and trastuzumab(2 years)
- Correlation of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer)(Baseline)
- Correlation of HER2 mutation with tumor grade (1-2 vs. 3)(Baseline)
- Correlation of HER2 mutation with tumor staging at initial diagnosis (I vs. II or III vs. IV)(Baseline)
- Correlation of HER2 mutation with disease free survival(2 years)
- Occurrence of HER2 mutation in paired primary and metastatic sites(Baseline)
研究者
相似试验
已完成
2 期
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast CancerHER2-positive Breast CancerStage II Breast CancerStage IIIA Breast CancerNCT01688609National Cancer Institute (NCI)18
进行中（未招募）
2 期
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerBreast NeoplasmsHER2/Neu PositiveGeriatric Health ServicesNCT01273610City of Hope Medical Center40
终止
2 期
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerMale Breast CancerNCT01868503Stanford University7
已完成
2 期
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast CancerBreast CancerNCT00470704Nancy Lin, MD87
已完成
2 期
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal AdenocarcinomaMetastatic Colorectal CancerNCT00574171University of Wisconsin, Madison29